Garniglipt 50/1000 Tablet is a fixed-dose combination medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The combination of these two agents provides complementary mechanisms to effectively reduce fasting and postprandial blood glucose levels. Garniglipt 50/1000 is typically prescribed when monotherapy with either agent is insufficient to achieve adequate glycemic control or when a combination therapy is preferred to optimize treatment outcomes. It is important to use this medication as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of pancreatitis. Common adverse effects may include gastrointestinal disturbances and hypoglycemia, particularly when used with other antidiabetic agents. Regular follow-up and laboratory monitoring are recommended to ensure safety and efficacy.